Annias Immunotherapeutics Inc.
Targeting immunotherapy to a virus present in tumors
This article was originally published in Start Up
Every would-be developer of cancer immunotherapeutics faces the same basic problem: how to get the body's immune system to destroy cancerous cells without harming healthy ones. The founders of Annias Immunotherapeutics Inc. think they have found a way to help the body push through immune tolerance and become better able to seek and destroy solid tumors; the trick is targeting a virus that has recently been discovered to be present in certain types of tumors, but not in surrounding healthy tissue.